In this week’s video, Dr. Brian G.M. Durie explains the results of the A.R.R.O.W. trial, which proved the efficacy and safety of once-a-week dosing of Kyprolis for myeloma patients.

The FDA approval of once-weekly dosing of Kyprolis is effective, more convenient for patients, and doesn’t lead to additional toxicities.

Have a question? Submit it to

IMF Chairman and Co-Founder Brian G.M. Durie, MD welcomes your questions about the latest myeloma treatments, research, controversies and quality of life issues. If you have a question you think might be of interest to the myeloma community, please send to!

For questions of a specific personal nature, please call the IMF InfoLine coordinators at 800.452.2873 or email them at

Previous Post
FDA Weighs in On Immune Therapies
Next Post
What is the status of Empliciti® (elotuzumab), the new immunotherapy?

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.